Escitalopram

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Social Anxiety Disorder

Conditions

Social Anxiety Disorder

Trial Timeline

Mar 1, 2009 → Mar 1, 2010

NCT ID

NCT00902226

About Escitalopram

Escitalopram is a approved stage product being developed by Lundbeck for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00902226. Target conditions include Social Anxiety Disorder.

What happened to similar drugs?

6 of 15 similar drugs in Social Anxiety Disorder were approved

Approved (6) Terminated (4) Active (6)

✅Cariprazine + PlaceboAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅quetiapineAstraZenecaApproved

✅Pristiq + PlaceboPfizerApproved

✅Sertraline + PlaceboPfizerApproved

✅NefazodoneBristol Myers SquibbApproved

❌quetiapineAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00902564	Approved	Completed	Mar 1, 2009	Mar 1, 2010	Generalized Anxiety Disorder
NCT00902226	Approved	Completed	Mar 1, 2009	Mar 1, 2010	Social Anxiety Disorder
NCT00935246	Pre-clinical	UNKNOWN	Dec 1, 2008	Dec 1, 2016	Depression
NCT00442481	Approved	UNKNOWN	Feb 1, 2007	—	Major Depressive Disorder
NCT00708240	Approved	UNKNOWN	Jan 1, 2007	Dec 1, 2010	Obsessive Compulsive Disorder
NCT00397059	Approved	Completed	Dec 1, 2006	Oct 1, 2007	Healthy
NCT00456937	Approved	Completed	Jul 1, 2006	Sep 1, 2008	Schizophrenia
NCT00464191	Approved	Terminated	Apr 1, 2006	Mar 1, 2009	Bipolar Disorder
NCT00243477	Approved	Completed	Jan 1, 2006	Feb 1, 2012	Coronary Artery Disease
NCT00232700	Pre-clinical	Completed	Sep 1, 2005	Dec 1, 2008	Major Depressive Disorder
NCT00162968	Approved	Completed	Dec 1, 2004	Apr 1, 2007	Pain
NCT00229333	Approved	UNKNOWN	Dec 1, 2004	—	Depressive Syndrome
NCT00140257	Approved	UNKNOWN	Nov 1, 2004	—	Depression
NCT00148447	Phase 3	Completed	Nov 1, 2004	Sep 1, 2005	Schizophrenia

Competing Products

20 competing products in Social Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
LY686017 + paroxetine + placebo	Eli Lilly	Phase 2	35
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Cariprazine + Placebo	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
quetiapine	AstraZeneca	Phase 3	32
quetiapine	AstraZeneca	Phase 2/3	38
Seroquel + Sugar Pill	AstraZeneca	Phase 3	40
quetiapine	AstraZeneca	Approved	43
Pristiq + Placebo	Pfizer	Approved	43
Venlafaxine ER	Pfizer	Phase 3	40
Ziprasidone + Sertraline	Pfizer	Phase 2	35
Sertraline + Placebo	Pfizer	Approved	35
Nefazodone	Bristol Myers Squibb	Approved	43
Cipralex + Placebo	Lundbeck	Phase 2	32
BHV-0223 + Placebo	Biohaven	Phase 2/3	32
VQW-765 + Placebo	Vanda Pharmaceuticals	Phase 3	37
PH94B	Vistagen Therapeutics	Phase 3	22
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray	Vistagen Therapeutics	Phase 2	32
PH94B Nasal Spray + Placebo Nasal Spray	Vistagen Therapeutics	Phase 3	22